Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Drug Delivery
Novo Nordisk to buy drug delivery firm Emisphere
by Michael McCoy
November 14, 2020
| A version of this story appeared in
Volume 98, Issue 44
Credit: Novo Nordisk
Novo Nordisk uses Emisphere's Eligen technology to create an oral form of the diabetes drug semaglutide.
Novo Nordisk will pay $1.8 billion to acquire Emisphere Technology, a US firm with technology for creating oral versions of biologic drugs that otherwise would have to be injected. Novo licenses the technology to formulate semaglutide, a diabetes drug it sells as Rybelsus. Emisphere’s technology is based on carriers, such as salcaprozate sodium, that enhance absorption of both small and large molecules.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X